Beyond GLP-1: Ascletis’ Oral Amylin Agonist ASC36 Signals a New Era in Obesity Treatment

Despite a surge in GLP-1 receptor agonists for weight management, nearly 40% of obese individuals fail to achieve significant weight loss with current therapies. Now, Ascletis Pharma is poised to disrupt the landscape with ASC36, an oral amylin receptor agonist demonstrating compelling efficacy and bioavailability – potentially offering a more scalable and accessible solution to the global obesity crisis.

The Promise of Amylin: A Different Pathway to Weight Control

While GLP-1s have dominated recent headlines, amylin, a hormone co-secreted with insulin, represents a complementary and potentially synergistic approach to weight management. Amylin slows gastric emptying, suppresses glucagon secretion, and promotes satiety – all crucial mechanisms for reducing food intake and achieving weight loss. However, delivering amylin effectively has been a long-standing challenge. Historically, amylin analogs required frequent injections. ASC36, leveraging Ascletis’ proprietary Peptide Oral Transport ENhancement Technology (POTENT), aims to overcome this hurdle.

POTENT: Breaking the Oral Peptide Barrier

The key to ASC36’s potential lies in POTENT, a technology designed to dramatically improve the oral bioavailability of peptides. In non-human primate (NHP) studies, ASC36 achieved an absolute oral bioavailability of 6% to 8% at steady state – a significant breakthrough for oral peptide delivery. This translates to a longer elimination half-life, ranging from 116 to 167 hours, supporting once-daily dosing and potentially even less frequent administration. This is a critical advantage over some existing therapies requiring more frequent injections.

ASC36 Demonstrates Superior Weight Loss in Preclinical Models

Preclinical data is remarkably promising. NHP studies showed that ASC36 oral tablets reduced mean body weight by up to 13.2% from baseline after just seven days of once-daily dosing, accompanied by a significant reduction in food intake. Even more compelling, in a head-to-head comparison with eloralintide and petrelintide in a diet-induced obese (DIO) rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction, respectively. These results suggest a potentially superior efficacy profile.

Manufacturing Scalability and Lower Dosage Potential

Beyond efficacy, ASC36’s improved bioavailability could translate to a lower required dose compared to other oral peptide agonists. This, in turn, offers significant advantages in manufacturing scalability and cost-effectiveness. A lower dose per patient reduces the overall peptide demand, streamlining production and potentially lowering the cost of treatment – a crucial factor for widespread accessibility.

The Road Ahead: IND Submission and the Future of Oral Amylin Agonists

Ascletis plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. This marks a pivotal moment, not just for Ascletis, but for the entire field of obesity treatment. Success with ASC36 could pave the way for a new generation of oral peptide therapies, offering patients a more convenient and potentially more effective alternative to existing options.

Beyond ASC36: A Broader Amylin Pipeline

ASC36 is just one piece of Ascletis’ ambitious amylin-focused pipeline. The company is also developing an oral small molecule amylin, and a once-monthly subcutaneous injectable peptide amylin, demonstrating a comprehensive strategy to address diverse patient needs. This multi-pronged approach, coupled with their proprietary AI-assisted drug discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, positions Ascletis as a key player in the evolving metabolic disease landscape.

Frequently Asked Questions About Oral Amylin Agonists

What is the significance of oral bioavailability for peptide drugs?

Historically, peptides have been poorly absorbed when taken orally due to their large size and susceptibility to degradation in the digestive system. Achieving meaningful oral bioavailability, as demonstrated with ASC36 and POTENT, is a game-changer, enabling convenient and patient-friendly administration.

How does amylin differ from GLP-1 in its mechanism of action?

While both amylin and GLP-1 promote weight loss, they act through different pathways. GLP-1 primarily enhances insulin secretion and suppresses glucagon. Amylin, on the other hand, slows gastric emptying, increases satiety, and also modulates insulin and glucagon secretion, offering a complementary effect.

What are the potential long-term implications of successful oral amylin agonists?

If ASC36 and similar drugs prove successful in clinical trials, we could see a significant shift in obesity treatment paradigms. Oral amylin agonists could become a first-line therapy for many patients, offering a convenient, effective, and potentially more affordable option compared to current injectable treatments.

The development of ASC36 represents a significant step forward in the fight against obesity. As we move closer to the IND submission and potential clinical trials, the future of weight management looks increasingly promising, with oral amylin agonists poised to play a central role. What are your predictions for the impact of oral peptide therapies on the obesity epidemic? Share your insights in the comments below!